Terlipressin vs HCG
Head-to-head comparison of Terlipressin and HCG for research applications. Both peptides are studied for Reproductive Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Terlipressin | Hcg |
|---|---|---|
| Category | Reproductive / Hormonal | Hormonal / Reproductive |
| Mechanism | Terlipressin is a triglycyl-lysine vasopressin prodrug. | HCG binds to the LH/CG receptor (LHCGR) on Leydig cells and theca cells with high affinity. In males, this stimulates intratesticular testosterone production, spermatogenesis, and maintains testicular volume. |
| Evidence Rating | A — Approved Medication with Strong Human Data | A — FDA Approved |
| Clinical Status | FDA-approved (Terlivaz for hepatorenal syndrome type 1, September 2022) | FDA-approved for anovulation/infertility, hypogonadotropic hypogonadism, prepubertal cryptorchidism. |
| Safety Profile | Respiratory failure: observed in 11% of terlipressin-treated patients vs 2% placebo in CONFIRM trial; FDA boxed warning for serious or fatal respiratory failure; Abdominal pain and diarrhea (common) | Common: injection site reactions, headache, fatigue, mood changes; Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort |
| Route | Intravenous bolus injection | Subcutaneous injection |
| Dose Range | HRS-1: 0.85 mg IV every 6 hours; may increase to 1.7 mg every 6 hours if serum creatinine has not decreased by >=30% by day 4. Variceal bleeding: 2 mg IV initially, then 1-2 mg every 4-6 hours for up to 48 hours. | 250-500 IU per injection (750-1500 IU/week) |
| Frequency | Every 6 hours | 3 times per week |
| Molecular Weight | ~1227.4 g/mol | ~36,700 g/mol (glycoprotein) |
| Half-Life | ~50 minutes (parent); ~2-3 hours (active lysine vasopressin metabolite) | ~24-36 hours |
Overview
Terlipressin and HCG are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Terlipressin — Mechanism & Evidence
Terlipressin is a synthetic vasopressin analog (MW ~1227.4 g/mol) that acts as a prodrug, slowly converted by tissue peptidases to the active metabolite lysine vasopressin. Terlipressin has been used in Europe for decades for variceal bleeding and hepatorenal syndrome. It acts primarily via V1a receptors to cause splanchnic vasoconstriction, improving renal perfusion in the context of portal hypertension.
Key claims: Improves renal function in hepatorenal syndrome type 1; First FDA-approved therapy for hepatorenal syndrome; Effective for acute variceal bleeding.
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
HCG — Mechanism & Evidence
Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone (MW ~36,700 g/mol) composed of an alpha subunit (shared with LH, FSH, TSH) and a unique beta subunit. Naturally produced by placental trophoblasts during pregnancy, pharmaceutical HCG binds LH/CG receptors in the gonads, stimulating testosterone production in Leydig cells and progesterone in the corpus luteum. It is FDA-approved for multiple reproductive indications and is widely used off-label to maintain testicular function during testosterone replacement therapy (TRT).
Key claims: Maintains testicular function during TRT; Preserves fertility during testosterone use; Triggers ovulation in fertility treatment.
Shared Research Applications
Both peptides are studied for: Reproductive Health.
Terlipressin is also researched for: Critical Care.
HCG is also researched for: Hormonal.
Safety Considerations
Terlipressin: Respiratory failure: observed in 11% of terlipressin-treated patients vs 2% placebo in CONFIRM trial; FDA boxed warning for serious or fatal respiratory failure Abdominal pain and diarrhea (common) Peripheral ischemia: digital ischemia, skin necrosis, and intestinal ischemia reported
HCG: Common: injection site reactions, headache, fatigue, mood changes Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort Females: ovarian hyperstimulation syndrome (OHSS) — potentially serious
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe